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cult. Lack of diagnostic certainty or possible distress related to a
positive result from diagnostic testing could limit the application of
new testing technologies. The objective of this paper is to quantify
respondents’ preferences for obtaining AD diagnostic tests and to
estimate the perceived value of AD test information. Methods: Dis-
crete-choice experiment and contingent-valuation questions were
administered to respondents in Germany and the United Kingdom.
Choice data were analyzed by using random-parameters logit. A
probit model characterized respondents who were not willing to take
a test. Results: Most respondents indicated a positive value for AD
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.1016/j.jval.2015.10.011.testing preferred brain imaging without the use of radioactive
markers. German respondents had relatively lower money-
equivalent values for test features compared with respondents in
the United Kingdom. Conclusions: Respondents preferred less inva-
sive diagnostic procedures and tests with higher accuracy and
expressed a willingness to pay up to €700 to receive a less invasive
test with the highest accuracy.
Keywords: discrete-choice experiment (DCE), Alzheimer’s disease (AD),
diagnostic test information, money-equivalent value (MEV).
Copyright & 2016, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Alzheimer’s disease (AD) is the most common cause of dementia
in older adults and affects approximately 7.3 million people in
Europe. The worldwide cost of AD care is estimated to be €440
billion [1]. Symptoms of AD include memory deterioration, pro-
gressive difﬁculty with language and the ability to communicate,
declining ability to perform routine tasks, and personality and
mood changes.
Despite the existence of standardized medical criteria [2,3],
clinical diagnosis remains difﬁcult. With the use of standardized
criteria, diagnosis is approximately 81% sensitive and 70% spe-
ciﬁc compared with the gold standard—pathology at autopsy [4].
The accuracy levels have not changed since the publication of the
criteria in 2001; Beach et al. [5] reported in 2012 that concordance
of clinical diagnosis and pathologic ﬁndings is still around 71%
for both sensitivity and speciﬁcity in patients with a probable
clinical AD diagnosis.
No general tool exists for making a deﬁnitive diagnosis of AD.
There is a new approach, however, to detecting preclinical AD in
older adults. The blood test predicted AD within a 2- to 3-year
timeframe, with over 90% accuracy [6]. Several other biomarkersaccompany the progression of AD and are hypothesized to
develop at different stages of the disease. It is a widely accepted
assumption that an initiating event in the development of AD is
the accumulation of β-amyloid plaques in the brain, which are
targeted by using diagnostic tests such as β-amyloid positron
emission tomography (PET) tracer or indirectly by using cerebro-
spinal ﬂuid. After a time, neuronal dysfunction and neurodegen-
eration with brain atrophy follow. Fluorodeoxyglucose positron
emission tomography (FDG-PET) and magnetic resonance imag-
ing (MRI) are used to detect these developments [7].
Biomarker tests vary in their invasiveness. MRI, for example,
requires patients to lie in a machine that takes images of the
brain. PET tests also take pictures of the brain, but as a prereq-
uirement, a radioactive marker or dye is injected into blood in
order to monitor tracer activities in the brain. To collect samples
of cerebrospinal ﬂuid, a needle is inserted into the spine to
remove the ﬂuid. The tests vary in reliability and accuracy, with
sensitivity and speciﬁcity ranging from 65% to 95% [4,8].
There is an unmet need for improved test precision. The
proposal by Dubois and colleagues [9] to include pathologically
linked biomarkers of AD in research diagnostic criteria aims to
reduce the frequency of false-positive diagnosis and increase thefor this research.
enburg, IGM Institut Gesundheitsökonomie und Medizinmanage-
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symptomatic stage. Studies by Elson [10], Mattsson et al. [11], and
Turnbull et al. [12] suggest that most patients are keen to know
the cause of their symptoms, even if the cause is AD. The clinical
value of a diagnostic test, however, depends heavily on the
potential for treating the disease. Currently, there is no effective
treatment for AD. In the absence of treatment beneﬁts with
regard to mortality, morbidity, or quality of life, the value of
diagnostic tests remains questionable.
The aim is to quantify the preferences of older adults without
memory problems for AD test technologies and the perceived
value of diagnostic information by applying discrete-choice
experiment (DCE) and contingent-valuation (CV) questions [13–
15].Materials and Methods
Study Designs
The survey presented respondents with a series of DCE questions
(see Appendix A in Supplemental Materials at: http://dx.doi.org/
10.1016/j.jval.2015.10.011 [16–26]). The levels and analytical vari-
able names used for each attribute are summarized in Appendix
A (in Supplemental Materials at: http://dx.doi.org/10.1016/j.jval.
2015.10.011). Each question included two virtual diagnostic test
proﬁles and a no-test option. Each proﬁle was deﬁned by three
attributes based on a review of relevant literature, consultation
with clinical experts, and face-to-face interviews with target
populations in Germany and the United Kingdom. The attributes
were diagnostic test type; test precision (false-positive or false-
negative test results); and test cost. Pretest interviews indicated
that respondents had difﬁculty understanding the distinction
between false-negative results and false-positive results and
therefore had difﬁculty evaluating both types of errors in the
same DCE question. The presentation of diagnostic test impreci-
sion was improved, and the questions were divided into two sets
of questions: one that deﬁned imprecision as the rate of false
positives, and another that deﬁned imprecision as the rate of
false negatives. The sequence of the two groups of questions was
randomly assigned.
The attribute levels were chosen to encompass the range of
levels described in the literature as well as the range over which
respondents were willing to accept tradeoffs in pretest inter-
views. Diagnostic test cost was included as an attribute in the
choice questions to estimate the money-equivalent value (MEV),
also called “willingness to pay” (WTP), for improvements in the
levels of the diagnostic test attributes. The range of costs was
chosen based on the likely limit of respondents’ willingness to
accept tradeoffs between cost and different levels of the diag-
nostic test attributes. We expected a majority of respondents to
reject the highest cost shown, even when the associated test
attributes were all set at the most desirable levels.
In addition to the DCE question format, CV questions were
included to capture the value of diagnostic test information
assuming that treatment is available to patients. Respondents
were asked to consider the following scenario: 1) “If the test says
you do have AD, you would get a treatment that would keep your
memory problems from getting worse for 1 year”; 2) “If the test
says you do not have AD, you would get a treatment that would
keep your memory problems from getting worse for 2 months”;
and 3) “The test uses brain imaging with radioactive marker.”
Using a double-bounded, dichotomous-choice format (see
Appendix B in Supplemental Materials at: http://dx.doi.org/10.
1016/j.jval.2015.10.011 for the CV question format), respondents
were then asked what they would pay for this diagnostic test. The
resulting responses made it possible to identify two types ofrespondents among those who always chose the no-test option
in the DCE questions: 1) respondents who would be interested in
additional testing and had a zero or positive MEV for diagnostic
information; and 2) respondents who would not be interested in
additional testing and had a negative MEV for diagnostic
information.
While developing the surveys, we used a robust forward-
backward translation. Both surveys were then pretested with a
sample of respondents aged 60 years or more in face-to-face
interviews in the United Kingdom (15 pretests) and Germany (18
pretests). The survey also collected data on demographic and
socioeconomic characteristics, health history, experience with
AD diagnostic tests, and experience in caring for or knowing
someone with AD (see Appendix C in Supplemental Materials at:
http://dx.doi.org/10.1016/j.jval.2015.10.011 for the English version
of the survey). The Research Triangle Institute’s Ofﬁce of
Research Protection and Ethics approved the study design.
Experimental Design
The experimental design optimized the assignment of the three
attributes and their levels into pairs of virtual test proﬁles. A
fractional factorial experimental design with 36 choice questions
was constructed using a D-optimal algorithm in the Statistical
Analysis System (SAS Institute, Cary, NC) [13,27,28]. Choice
questions were divided into six versions of six questions each.
For each pair, respondents were asked to indicate whether they
would choose one of the two virtual tests or the no-test option.
Figure 1 presents an example DCE question for the false-negative
error (Appendix D in Supplemental Materials at: http://dx.doi.org/
10.1016/j.jval.2015.10.011 contains the German version). Each
respondent was given 12 questions from the design (six ques-
tions with incidence of false-positive errors and six questions
with incidence of false-negative errors). For the assigned version,
each respondent also was randomly assigned to answering either
the false-positive choice questions ﬁrst or the false-negative
choice questions ﬁrst.
Data Collection
Sample-size power calculations represent a technical challenge
in DCEs. Based on the existing DCE literature [29,30], with a
sample of 300 to 350 respondents, the accuracy of estimation is
generally good but representativeness is limited [13,31,32].
The hypothesis that numerous respondents might not be
interested in taking the AD diagnosis test led to the decision to
target a bigger sample size. Sample sizes of 800 for each country
provided better representativeness and allowed for sufﬁcient
power for analyzing the subsample that had a positive value for
diagnostic test information.
The German and UK respondents were recruited from GfK’s
Custom Research online panels. To qualify for inclusion in this
study, respondents had to be able to read and understand Ger-
man for the German sample or English for the UK sample; be
aged 60 years or older; not have memory problems or dementia;
and not currently take a prescription medication to treat AD.
Data Analysis
The preference data were analyzed by using random-parameters
logit models with NLOGIT 4.0 (Econometric Software Inc., Plain-
view, NY). Random-parameters logit avoids potential estimation
bias from unobserved taste heterogeneity among respondents by
estimating a distribution of tastes for each preference parameter
[33,34]. Taste distributions were assumed to be normal except for
cost, which was estimated as a nonrandom variable [33]. Other
distributional assumptions yielded implausible estimates.
Figure 1 – Example DCE Question, UK Survey, False-Negative Version. DCE, discrete-choice experiment. (Color version of
ﬁgure is available online.)
*The coefﬁcients were plotted against the price points to see if
the cost attribute is linear. The R-squared values were between
0.89 and 0.93 for the German sample and between 0.93 and 0.98
for the UK sample.
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choice task. The independent variables were levels of each of
the attributes in each proﬁle. All attributes (see Appendix A in
Supplemental Materials at: http://dx.doi.org/10.1016/j.jval.2015.
10.011) were included in the model as effects-coded variables
except personal cost and the no-test option. After speciﬁcation
testing, personal cost was speciﬁed as a linear numeric variable.
The no-test option was speciﬁed as a dummy variable.
Effects coding normalizes the mean level effect at zero for each
attribute, rather than at the omitted level as in dummy coding
[35]. The procedure produces a parameter estimate for all level
categories. Standard errors were calculated by using the Krinsky-
Robb method [36]. The resulting log-odds estimates relative to the
mean effect indicate the relative strength of preference for each
level. Positive parameter estimates indicate choice probabilities
larger than the mean effect, whereas negative parameter esti-
mates indicate choice probabilities smaller than the mean effect.
For ease of comparison and to eliminate scale differences
between the two countries, the model results are rescaled from
0 to 10, using linear transformation of β-coefﬁcients from 0 (the
least preferred level) to 10 (the most preferred level).
The relative importance of an attribute conditional on the range
of levels presented is determined by the relative difference between
the most important and the least important levels. Thus, the
mean relative importance score for each factor is interpreted as
the relative value of an improvement from the worst level to the
best level.
The preference-score index has no meaning except in relative
comparisons. Rescaling of parameter estimates by using a con-
tinuous attribute as a numeraire converts parameter estimates
into a more intuitive measure of preference intensity. In partic-
ular, relative importance is indicated by the MEV of utility
differences. For the speciﬁed linear-additive indirect utility func-
tion, MEV for test characteristics is the expected mean
compensating-surplus welfare measure for respondents with an
interest in the speciﬁc test attribute. Ex ante MEV accounts for
the probability of being “in the market” for a particular test and
thus is the value of having the test in the individual’s choice set.The estimates were calculated by using the standard random-
utility log-sum formula [37]:
MEV¼ lnðe
Ui þ eUOPTOUT Þ lnðeUOPTOUT Þ
∂U=∂Cost
where Ui is the utility of a test of speciﬁed type and precision,
UOPTOUT is the utility of not testing, and the denominator is the
constant marginal utility of income.
Given the importance of obtaining a valid estimate of the
marginal utility of income, a validity test of sensitivity to scope
was included to test the hypothesis that respondents paid
attention to absolute cost levels and did not interpret the cost
levels simply as “low,” “medium,” and “high.” To test this
hypothesis, each respondent was given only four cost levels. Half
of the German respondents were given €240, €360, €600, and €960
per diagnostic test and the other half €240, €360, €600, and €1200
per diagnostic test. Half of the UK respondents were given £200,
£300, £500, and £800 per diagnostic test and the other half £200,
£300, £500, and £1000 per diagnostic test. Attention to absolute
costs is indicated by greater sensitivity to cost in the arm with the
wider range of costs.*
In this study, some respondents chose the no-test alternative
in all the DCE questions and did not express an interest in the
diagnostic test described in the CV question even at zero cost. The
respondents provided no usable information for quantifying pref-
erences for diagnostic test features and thus were dropped from
the choice model. We estimated a probit model to investigate the
effects of respondents’ demographic characteristics, experiences,
and perceptions of AD and its tests on interest in test information.
Missing data on personal characteristics were replaced with mean
values of respondents who provided the data.
The preference data included respondents who picked “Addi-
tional Test A” or “Additional Test B” for at least one of the DCE
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tional Test” but stated an interest in an additional diagnostic test
in the CV questions if the test were offered at low or zero cost.
We analyzed the choice data by specifying indirect utility U as:
U¼βWITHOUT_MARKER WITHOUT_MARKERþβWITH_MARKER
WITH_MARKERþβSPINAL_TAP  SPINAL_TAP
þβFALSE_5%  FALSE_5%þβFALSE_15%  FALSE_15%
þβFALSE_30%  FALSE_30%þβOPTOUT OPTOUTþβCOST  COST,
where OPTOUT is an indicator variable equal to one for the “No
Additional Test” option and zero otherwise. βOPTOUT is deﬁned
relative to the mean test utility, which is zero for all attributes
except cost. We removed the effect of the mean cost by calculat-
ing no-test utility as the dummy-variable parameter minus the
cost parameter times the mean cost. COST is a continuous
variable set at the level shown in each question. We estimated
the same choice model for each country separately. Speciﬁcation
tests supported combining false-positive and false-negative
imprecision levels in a single attribute.yResults
Sample Characteristics
In Germany, of the 6377 individuals invited to participate in the
survey, 1630 responded, 876 were eligible and consented, and 815
completed the survey. In the United Kingdom, of the 7852
individuals invited to participate in the survey, 1580 responded,
860 were eligible and consented, and 800 completed the survey. A
total of 281 respondents (167 German; 114 UK) chose the no-test
alternative in all the DCE questions and did not express an
interest in the diagnostic test described in the CV question even
at zero cost and thus were dropped from the choice model.
Another 33 respondents (17 German; 16 UK) were dropped from
the choice model because they always chose “Additional Test A”
or “Additional Test B” in all DCE questions, which indicated that
they did not pay close attention to the questions given. The
median reported completion time was 15 minutes. Summary
statistics are reported in Table 1.
The German respondents had less experience of AD. About a
third of the German respondents had a family member or friend
with AD or any other kind of serious memory problem compared
with about half of the UK respondents. In both countries,
however, one-third of the respondents provided care for someone
with AD or serious memory problems. Only 4.3% and 2.5% of the
German and UK respondents, respectively, stated that they had
taken an AD test. In addition, overall, 32% did not think that an
AD test is useful if there is no cure and no way to slow disease
progression (Germany 37%; UK 27%).
Contingent Valuation: Who Is Willing to Take an AD Test?
A double-bounded, dichotomous-choice CV question elicited the
respondents’ direct WTP for a brain imaging test using a radio-
active marker with 15% imprecision. About one-third of the
respondents (184 German; 130 UK) were not willing to pay for
diagnostic information in the DCE question. About 53% of these
respondents who were not willing to pay, however, indicated that
they would be interested in taking a diagnostic test at low or zero
cost in the CV question.yLog-likelihood ratio tests suggested the false-positive/false-
negative sequence (Germany: P value ¼ 0.995; UK: P value ¼ 0.765)
and information treatment (i.e., availability of treatment for AD)
(Germany: P value ¼ 0.148; UK: P value ¼ 0.105) had no statisti-
cally signiﬁcant effect on preferences for AD diagnostic testing.Choice-Model Estimates: What Are the Important Attributes
of an AD Test?
Table 2 compares rescaled log-odds mean preference weights and
standard deviations of the distribution of preference weights by
country for the 631 German and the 670 UK respondents who
indicated an interest in testing. In the DCE data, about 40% of the
German respondents and 34% of the UK respondents chose the
no-test alternative in every question.
The standard errors and deviations of these distributions
reported in Table 2 are also depicted in Figure 2. The German
respondents had greater taste heterogeneity than the UK
respondents. That is, there was less consensus among German
respondents about each diagnostic test feature than among the
UK respondents. The only exception is the middle-level test
imprecision of 15%, where both the German and the UK respond-
ents were in strong agreement.
There were no statistically signiﬁcant differences between the
samples from the two countries in mean preference-parameter
estimates for either test characteristics or cost. Test precision
strongly inﬂuenced diagnostic test preferences and was signiﬁ-
cantly more important than test technology. For the test-type
attribute, the German and UK respondents preferred brain imag-
ing without radioactive markers to brain imaging with radio-
active markers (Germany: P o 0.01, UK: P o 0.01); brain imaging
without radioactive markers to spinal tap (Germany: Po 0.01; UK:
P o 0.01); and brain imaging with radioactive markers to spinal
tap (Germany: P o 0.01; UK: P o 0.01).
Although mean parameters were similar, all standard-
deviation measures of taste heterogeneity for the German
respondents were signiﬁcantly larger than the estimates for UK
respondents except for 15% imprecision.
The Value of Diagnostic Information: What Is the MEV of AD
Tests?
The preference weights were used to calculate ex ante mean MEV
for AD test proﬁles. Although parameter weights between the two
countries were statistically similar, the strong nonlinearity in the
ex ante MEV ratio formula resulted in larger differences in those
values. Table 3 presents MEV estimates for all combinations of
test technology and test precision. Each MEV estimate indicates
the predicted value of having the diagnostic test as an option in
the individual’s choice set. The most valued diagnostic test was
brain imaging without radioactive markers with best test preci-
sion and with estimated MEVs of €342 among German respond-
ents and €704 among UK respondents. The least valued
diagnostic test was spinal tap, with worst test precision and
estimated MEVs of €49 and €37 among German and UK respond-
ents, respectively. In general, German respondents were willing
to pay less than UK respondents for improvements in test type
and test precision. All of the German MEV estimates except one
were less than the UK estimates and ﬁve of the nine differences
were statistically signiﬁcant.
Respondent Characteristics: Who Does Not Want to Know
Their AD Status?
Table 4 summarizes the effect of personal characteristics on the
likelihood of having an interest in the diagnostic test information.
Respondents who were more likely to have an interest in an
additional test included the UK respondents (P ¼ 0.034), male
respondents (P ¼ 0.095), respondents who thought an AD test is
useful even though there is no cure (P o 0.001), respondents who
thought a false-negative result would be devastating (P o 0.001),
respondents who thought their memory problems probably would
be much or somewhat less serious than AD if an additional test
Table 1 – Descriptive statistics.
Variable Overall
N ¼ 1301
German
respondents
n ¼ 631
UK
respondents
n ¼ 670
P value*
Male 56.5% 62.9% 50.5% o 0.001
Mean age in years (SD) 65.8 (4.6) 65.4 (4.5) 66.2 (4.7) 0.002
Has a college degree or higher 26.3% 31.4% 21.6% o 0.001
Current total annual household income (before any deductions for income tax,
national insurance, etc.) (£ in UK and € in Germany)
Less than £20,000 / Less than €24,000 38.5% 36.2% 40.6% 0.200
£20,000-£39,999 / €24,000-€47,999 36.8% 37.5% 36.2%
£40,000 or more / €48,000 or more 12.9% 14.1% 11.7%
Do not know or missing 11.8% 12.2% 11.5%
Has had a family member or friend with AD or any other kind of serious
memory problem
41.4% 32.8% 49.4% o 0.001
Has provided care for someone with AD or serious memory problems 35.5% 35.8% 35.4% 0.925
Has had a test for memory problems or AD 3.4% 4.3% 2.5% 0.082
Note. Percentages displayed exclude missing values.
AD, Alzheimer’s disease; SD, standard deviation.
* P values indicate the statistical signiﬁcance of differences between the UK and German respondents and are reported based on chi-squared
tests for categorical variables and Student’s t tests for continuous variables.
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o 0.001), and respondents who thought it somewhat or very likely
that researchers will ﬁnd an effective treatment for AD in the next
5 years (P ¼ 0.011). Respondents, however, would be less likely to
have interest in an additional test if they reported no existing
medical conditions (P ¼ 0.085), previously had a test for memory
problems or AD (P ¼ 0.120), or were not concerned about develop-
ing AD in the future (P o 0.001).Discussion
On the basis of the literature and the pretest results, we expected
to identify two different groups: (1) those who did not want to
know their AD status, and (2) those who did want to know and
were willing to accept the tradeoffs between diagnostic test
attributes and personal costs. Results from qualitative questions,Table 2 – Germany and United Kingdom rescaled choice-
Attribute Level
Rescaled Mean Preference Weights
Test type Brain imaging without radioactive marker
Brain imaging with radioactive marker
Spinal tap
Test imprecision 5%
15%
30%
No test 1, if no test was chosen; otherwise, 0
Test cost A continuous variable
Rescaled Standard Deviations of Preference-Weight Distributions
Test type Brain imaging without radioactive marker
Brain imaging with radioactive marker
Spinal tap
Test imprecision 5%
15%
30%
No test 1, if no test was chosen; otherwise, 0the CV data, and the DCE data conﬁrmed this expectation. The
questions that were answered are described below.
Who Was Willing to Take an AD Test?
The CV questions showed that a large percentage of respondents
were not willing to take a diagnostic test or did not state any
interest if asked about their WTP, perhaps for fear of receiving
bad news with little prospect of effective treatment. Depending
on the question format and the nationality of the population, 33%
to 40% were not interested in taking the AD diagnostic test. The
result is consistent with ﬁndings that a diagnosis of AD is often
made late in the disease continuum [38]. Indeed, many people
with dementia never receive a formal diagnosis at all [38]. Studies
have found that stigma can be an important inﬂuence on delays
in the recognition and diagnosis of dementia in primary care,
with some patients refusing to be assessed and caregivers also
being in denial or preferring not to know the diagnosis [39,40].model estimates.
Germany (N ¼ 631) UK (N ¼ 670)
Coefﬁcient Standard error Coefﬁcient Standard error
9.0946 0.8870 8.2469 0.5039
5.2005 0.7208 5.5920 0.4591
1.7451 1.0396 1.8255 0.6390
10.0000 1.1092 10.0000 0.6602
6.0402 0.6115 5.6643 0.3515
0.0000 1.1552 0.0000 0.6958
1.9769 2.2501 2.5488 1.2517
5.3259 0.0017 5.2085 0.0011
15.9881 1.1047 9.4408 0.5775
12.0153 0.8877 8.6638 0.5198
28.0035 1.5260 18.1046 0.7222
22.7278 1.1867 14.5778 0.7860
0.5828 1.0265 0.6308 0.5293
23.3106 1.4581 15.2086 0.9482
70.3128 3.3571 40.2972 1.8009
Figure 2 – Germany and UK Rescaled Choice-Model Estimates. Illustrates rescaled log-odds mean preference weights and
standard deviations of the distribution of preference weights by country for the 631 German and 670 UK respondents. The
circles and diamonds in the ﬁgure represent the relative preference weights for attribute levels for Germany and the UK,
respectively. The vertical bars around each relative preference weight indicate the 95% conﬁdence interval. If the conﬁdence
intervals between levels of a single attribute do not overlap, the preference weights are statistically signiﬁcantly different from
each other at the 5% level. The distributions around each preference-weight estimate indicate the estimated taste
heterogeneity among respondents. (Color version of ﬁgure is available online.)
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information was, indeed, correlated with various attitude and
health-history variables. The more aware and concerned people
were, the more likely they were to choose to take and pay for an
AD test. Given the importance of diagnostic test precision, it is
likely that more accurate, less invasive tests, as well as the
availability of better treatments, would also improve interest in
AD diagnostic information. Because of the respondents who didTable 3 – Money-equivalent values relative to no test (se
Test Technology Test Imprecision
Spinal tap False ¼ 30%
False ¼ 15%
False ¼ 5%
Brain imaging with radioactive marker False ¼ 30%
False ¼ 15%
False ¼ 5%
Brain imaging without radioactive marker False ¼ 30%
False ¼ 15%
False ¼ 5%
MEV, money-equivalent value; DCE, discrete-choice experiment.
* At the time of the study, the exchange rate was £1 ¼ €1.26.
† Numbers in parentheses are 95% conﬁdence intervals.not state any preference, the choice-model estimates and the
MEVs analyzed data only from respondents who were interested
in taking the AD test.
What Were the Important Attributes of an AD Test?
Respondents who had an interest in taking an AD test preferred
the less invasive diagnostic procedures. In particular, thelected comparisons).
MEV in €*,† P value
Germany (N ¼ 631) UK (N ¼ 670)
DCE ESTIMATES
49 (30, 68) 37 (23, 51) 0.33
104 (72, 136) 126 (90, 162) 0.38
164 (117, 211) 284 (211, 357) o 0.01
76 (49, 103) 85 (59, 111) 0.63
155 (113, 197) 257 (201, 314) o 0.01
237 (178, 295) 506 (410, 601) o 0.01
121 (80, 163) 147 (104, 189) 0.41
235 (175, 295) 397 (319, 475) o 0.01
342 (265, 419) 704 (590, 818) o 0.01
Table 4 – Likelihood of having interest in an addi-
tional test for given respondents’ characteristics.
Respondents’ characteristics Effect on likelihood of having
interest in an additional test
for AD
Pooled samples (N ¼ 1582)
UK resident 3.99% (0.31%, 7.66%)*
Male 3.07% (0.53%, 6.68%)†
Respondent’s age 0.15% (0.51%, 0.21%)
Married 1.78% (1.86%, 5.42%)
Reports no existing medical
conditions
3.87% (8.50%, 0.77%)†
Has had a test for memory
problems or AD
8.70% (21.28%, 3.88%)‡
Provides care for someone
with AD
3.40% (1.35%, 8.14%)
Thinks that an AD test is
useful even though there is
no cure and no way to slow
the progression of AD
19.53% (15.49%, 23.57%)§
Not at all concerned about
developing AD in the future
8.50% (12.20%, 4.80%)§
Thinks that a false-negative
would be the worse result
7.69% (4.17%, 11.20%)§
Thinks that memory problems
probably would be much or
somewhat less serious than
AD if an additional test said
the reason for the memory
problem was not AD
6.48% (2.93%, 10.03%)§
Thinks that it is very likely or
somewhat likely
researchers will ﬁnd an
effective treatment for AD
in the next 5 years
4.91% (1.13%, 8.69%)*
Note. Values in parentheses are the 95% conﬁdence intervals.
AD, Alzheimer disease; UK, the United Kingdom.
* Signiﬁcant at 5%.
† Signiﬁcant at 10%.
‡ Signiﬁcant at 15%.
§ Signiﬁcant at 1%.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 6 6 – 7 472majority of respondents in Germany and the United Kingdom
preferred brain imaging without radioactive markers, followed by
brain imaging with radioactive markers, and ﬁnally spinal tap.
The result is consistent with a study in older patients, in which
lumbar puncture was cited as the strongest disincentive for
participation in clinical research [41]. Taste heterogeneity was
larger for the German cohort than for the UK cohort and was
particularly large for no-test utility.How Much Were Respondents Willing to Pay?
Respondents preferred the tests with higher accuracy and indi-
cated signiﬁcantly higher monetary values for more accurate
tests. The mean MEV for the least invasive, most accurate test
was €342 and €704 for the German and UK samples, respectively.
Advertised prices for brain scans in UK private clinics range from
approximately €300 to €1500 equivalents. We found, however,
large taste variation in preference parameters relative to cost.
Although the preference for less invasive procedures might be
related to patient convenience, higher WTP for more accurate
diagnosis could have direct economic and public healthconsequences. The economic cost of false-positive diagnoses of
dementia has been explored in a US study [42]. That study found
that persons with false-positive dementia diagnoses made Med-
icare claims that for were signiﬁcantly (P o 0.001) more expen-
sive, costing $11,294 compared with $4,065 for true negatives.Were There Differences between UK Respondents and German
Respondents?
Despite the fact that the ordinal structure of the preferences did
not vary between the UK and German populations, the different
models discovered differences in taste heterogeneity, WTP, and
person-speciﬁc attributes, which led to a rejection of the AD
diagnostic testing. The differences could be related to the fact
that the study populations differed by the percentage of respond-
ents who were familiar with AD through a friend or family
member and who had serious memory problems. Moreover, the
percentage of male respondents varied, whereas age, annual
household income, and the percentage of respondents who
provided care to someone with AD did not vary dramatically.
Both populations had a low percentage of respondents who had
tested for AD before. Choice-model estimates for the attributes of
test type and test precision did not vary much between the two
populations. The test cost coefﬁcients varied to a great extent.
Also, the standard deviations were different, leading to the
conclusion of great differences in taste heterogeneity. That is,
there was less consensus among the German respondents about
each test feature than among the UK respondents. The fact that
test cost coefﬁcients were different could be analyzed in more
detail by estimating the MEVs. The UK respondents were willing
to pay twice as much for the most preferred AD testing option
compared with the German respondents (€704 versus €342).
Finally, the likelihood of having (no) interest in an additional
test for AD was found to be greatly inﬂuenced by nationality.
No treatments are currently available to cure or stop the
progression of AD; however, interventions are offered to support
and improve the lives of people with AD, including pharmaceutical
treatments and nonpharmaceutical interventions [38,43]. Our
study indicates that people are willing to pay for diagnostic clarity,
even in the absence of viable treatment options [15]. A study by
Kopits and colleagues [44] studied WTP for AD genetic testing and
found that genetic risk information was valuable, even if such
information has no therapeutic value. Similarly, Green and col-
leagues [45] disclosed AD genotype information to asymptomatic
adults and found psychological beneﬁts to those with negative test
results and only transient distress to those with positive results.
The ﬁndings are consistent with previous research showing that
people dislike ambiguous, uncertain situations and prefer cer-
tainty, even in the case of situations with negative consequences.
Our analysis had a number of limitations. Although the
respondents were recruited at different ages above 60 years and
from different regions in the consumer panels, the panels are not
strictly representative of the general older populations in the two
countries studied.
Dementia is a complex condition, and achieving a timely and
accurate diagnosis is challenging. AD often develops slowly, overlaps
with other comorbidities, and can include symptoms of cognitive
impairment similar to those of other conditions [46]. Furthermore,
the boundaries between subtypes of dementia are indistinct, and
most patients with dementia have been found to have mixed forms
[47]. The diagnostic complexities are difﬁcult to reﬂect in a preference
study where the number of addressed items needs to be balanced
against information overload to respondents. Thus, respondents
could have various expectations regarding their health state after
receiving a positive or negative diagnosis of AD. We controlled for
these expectations and found no signiﬁcant differences.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 6 6 – 7 4 73Also, a number of well-known factors can lead to hypothetical
bias in stated-preference surveys [48,49]. Our survey was designed
to mitigate hypothetical bias by offering respondents choices
among realistic tests using well-deﬁned attributes. However, the
respondents in this study made decisions independent of physi-
cians’ advice. The result is not reﬂective of real life, where diagnosis
is mainly in the hands of physicians and treatment decisions are at
best a collaborative effort of patients and physicians. Although not
likely to be predictive of clinical outcomes, increased interest in
patient-centric health care and shared decision helps shed light on
patients’ choices when not mediated strongly by clinical practice
guidelines and reimbursement considerations.Conclusions
Health care decision makers must prioritize health care inter-
ventions on the basis of the relationship between beneﬁt to
patients and costs imposed on society. Cultural and institutional
differences can inﬂuence prioritization decisions. The ﬁndings of
this study can help inform decisions on public needs and prior-
ities and can raise awareness of public preferences for diagnostic
information when therapeutic options are limited or nonexistent.
Our ﬁndings should be interpreted in light of the current phar-
macologic and behavioral interventions for dementia, which do
not prevent or alter disease progression. The use of these
interventions can only temporarily affect detrimental cognitive,
functional, and behavioral outcomes [38,50]. To aid in reducing
uncertainty in health policy making, a more targeted conﬁrma-
tory study needs to be conducted to verify and expand on these
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